2-乙氧基-5-甲酰基苯基硼酸 | 1003042-92-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-乙氧基-5-甲酰基苯基硼酸
• 中文别名: (2-乙氧基-5-甲酰基苯基)硼酸
• 英文名称: 2-Ethoxy-5-formylphenylboronic acid
• 英文别名: (2-ethoxy-5-formylphenyl)boronic acid
• CAS: 1003042-92-9
• 化学式: C₉H₁₁BO₄
• mdl: MFCD09752822
• 分子量: 193.995
• InChiKey: AKDKQQWBMKEDLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.41
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2931900090

反应信息

• 作为反应物：
  描述：

  2-乙氧基-5-甲酰基苯基硼酸 、 7-Bromo-6-methylquinazoline-2,4-diamine 在 potassium carbonate 、 钯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-(2,4-Diamino-6-Methylquinazolin-7-Yl)-4-Ethoxybenzaldehyde
  参考文献：
  名称：

  Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines

  摘要：

  Dihydrofolate reductase (DHFR) inhibitors such as trimethoprim(TMP) have long played a significant role in the treatment of bacterial infections. Not surprisingly, after decades of use there is now bacterial resistance to TMP and therefore a need to develop novel antibacterial agents with expanded spectrum including these resistant strains. In this study, we investigated the optimization of 2,4-diamnoquinazolines for antibacterial potency and selectivity. Using structure-based drug design, several 7-aryl-2,4-diaminoquinazolines were discovered that have excellent sub-100 picomolar potency against bacterial DHFR. These compounds have good antibacterial activity especially on gram-positive pathogens including TMP-resistant strains. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.059

文献信息

• Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines
  作者：Xiaoming Li、Mark Hilgers、Mark Cunningham、Zhiyong Chen、Michael Trzoss、Junhu Zhang、Lucy Kohnen、Thanh Lam、Chris Creighton、Kedar GC、Kirk Nelson、Bryan Kwan、Mark Stidham、Vickie Brown-Driver、Karen J. Shaw、John Finn

  DOI：10.1016/j.bmcl.2011.07.059

  日期：2011.9

  Dihydrofolate reductase (DHFR) inhibitors such as trimethoprim(TMP) have long played a significant role in the treatment of bacterial infections. Not surprisingly, after decades of use there is now bacterial resistance to TMP and therefore a need to develop novel antibacterial agents with expanded spectrum including these resistant strains. In this study, we investigated the optimization of 2,4-diamnoquinazolines for antibacterial potency and selectivity. Using structure-based drug design, several 7-aryl-2,4-diaminoquinazolines were discovered that have excellent sub-100 picomolar potency against bacterial DHFR. These compounds have good antibacterial activity especially on gram-positive pathogens including TMP-resistant strains. (C) 2011 Elsevier Ltd. All rights reserved.